A.R.T. Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

A.R.T. Advisors’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-7,219	Closed	-$448K	–	1844
2015 Q4	$448K	Buy	+7,219	New	+$508K	0.02%	907
2015 Q3	–	Sell	-25,662	Closed	-$2.5M	–	1782
2015 Q2	$2.5M	Buy	25,662 +16,974	+195%	+$1.62M	0.08%	371
2015 Q1	$812K	Buy	+8,688	New	+$739K	0.03%	736
2014 Q3	–	Sell	-8,949	Closed	-$513K	–	1679
2014 Q2	$513K	Buy	+8,949	New	+$454K	0.03%	764
2013 Q3	–	Sell	-3,372	Closed	-$178K	–	1628
2013 Q2	$178K	Buy	+3,372	New	+$148K	0.01%	1179

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

A.R.T. Advisors's MACK Position: Q1 2016 in Review

A.R.T. Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2016, closing a stake of 7,219 shares — an estimated $448K sold.

A.R.T. Advisors first reported a position in MACK in Q2 2013 and held it in 5 quarters. The position peaked at $2.5M in Q2 2015. 139 funds tracked by Wall St. Rank hold MACK as of Q1 2016.

A.R.T. Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
A.R.T. Advisors sold 7,219 Merrimack Pharmaceuticals, Inc. shares in Q1 2016, an estimated $448K.
A.R.T. Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 5 quarters.
A.R.T. Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $2.5M in Q2 2015.
139 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2016.

Based on A.R.T. Advisors's 13F filing for Q1 2016, filed 16 May 2016.